Simmunext latest news
Simmunext secures NWO Take-off Phase 2 funding
Simmunext secures NWO Take-off Phase 2 funding. Simmunext has secured funding from the Dutch Research Council (NWO) in the context of the Take-off Phase 2 program, which aims to stimulate and support ...
Simmunext Biotherapeutics to Showcase Cutting-Edge Innovations at BioEquity Europe
Simmunext Biotherapeutics is proud to announce its participation in the prestigious BioEquity Europe Meeting, scheduled to be held from May 12 to 14 in San Sebastian, Spain.As a leading biotechnology company dedicated ...
Simmunext will be presenting at the Radboudumc Investment Day
Simmunext will be presenting at the Radboudumc Investment DayGet ready for the third edition of Radboudumc Investment Day 2023 on October 12 in Nijmegen!Jointly organized by Radboudumc, Radboud University, Briskr and Oost ...
Simmunext secures financing from OostNL for clinical candidate selection
Financiering voor Simmunext: nieuwe therapie voor de behandeling van kanker. Met een investering vanuit het Vroege fase financiering Gelderland (VFF Gelderland) kan het Nijmeegse Simmunext Biotherapeutics BV verder met de ontwikkeling van ...
Radboud UMC researchers share their findings about the use of immunofilaments to slow growth of tumors and metastases in laboratory models.
Radboudumc researchers publish on the scientific evidence for the inhibition of tumor growth and metastasis using immunofilaments in preclinical model systems. Adoptive T cell therapy has successfully been implemented for the treatment ...